Self-Assembled PEGMEMA Diblock Copolymers for High Drug Loading
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing polymeric assemblies for drug delivery, particularly in cancer treatment, face challenges such as low drug loading capacity, incomplete drug conjugation leading to reactive sites, and non-capsulated drug aggregates, which result in undesired distribution and severe side effects.
Innovation Solution
Development of amphiphilic block copolymers that form well-defined micellar assemblies with high drug content and efficient conjugation, using cleavable linkers to release therapeutic agents under specific conditions, and optionally encapsulating additional drugs through non-covalent interactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If polymeric assemblies are used for drug delivery, then targeted drug delivery is achieved, but drug loading capacity is low
Solution Approach 1:
The polymeric assembly is segmented into distinct functional blocks: PEGMEMA blocks form the hydrophilic corona and micelle structure, while drug-bearing blocks form the hydrophobic core. This segmentation allows simultaneous achievement of high drug loading in the core and stable colloidal suspension at low concentrations, resolving the contradiction between low drug loading capacity and therapeutic efficacy
Solution Approach 2:
The invention uses a composite block copolymer structure combining PEGMEMA (polyethylene glycol methyl ether methacrylate) with drug-bearing polymeric segments. This composite material integrates the stabilizing properties of PEGMEMA with the drug-delivery functionality of the hydrophobic blocks, enabling high drug loading capacity while maintaining colloidal stability and targeted delivery capability
2Reliability
If post-polymerization conjugation is used to attach drugs, then drug attachment is achieved, but incomplete conjugation leaves reactive sites
Solution Approach 1:
The drug-bearing polymeric segments are pre-synthesized with reactive groups incorporated into the polymer backbone before assembly. This preliminary action ensures that all reactive sites are predetermined and controlled, eliminating the incomplete conjugation problem of post-polymerization methods while preventing undesired biological interactions through precise structural definition
Solution Approach 2:
The invention changes the chemical parameters of the polymer-drug conjugate by incorporating specific functional groups (carboxylic acid, amine, or hydroxyl groups) at controlled positions in the drug-bearing blocks. This parameter control ensures complete and uniform drug attachment while eliminating residual reactive sites that could cause harmful biological interactions
3Quantity of substance
If micellar formulations are used, then colloidal suspension is achieved, but drug loading capacity is low
Solution Approach 1:
The invention applies local quality by concentrating drug-bearing segments specifically in the hydrophobic core regions of the micelles, while the PEGMEMA blocks form the hydrophilic corona. This localized distribution achieves high drug loading capacity in the core while maintaining colloidal stability through the stabilizing corona, resolving the contradiction between drug loading and stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution achieves high drug loading, reduces polymer dosage, and minimizes side effects by targeted drug delivery, enhancing therapeutic efficacy while maintaining a well-defined structure.
Implementation Method 1
self-assembly of polymeric compounds is an attractive method for polymeric assembly formation
Implementation Method 2
amphiphilic block copolymers having polymer blocks with different physical and chemical properties to generate polymeric structures via self-assembly
Implementation Method 3
physical encapsulation via hydrophobic interactions
Implementation Method 4
L is a cleavable linker
Data Source
AI summary
This invention relates to polymer drug conjugates according to formula I, and their use for treatment of diseases such as cancer.